Imatinib Mesylate Tablet, Film Coated
Product Images NDC 72485-203

The text appears to be a statistical analysis of a medical study looking at the progression-free survival of patients receiving Imatinib mesylate and IFN+Arc-C treatment. The results are presented in Figure 1 where the progression-free survival rates for both treatments are compared using the "ITT Principle". The graph shows the number of patients with progression of their disease, the number of patients censored at discontinuation or last follow-up, the hazard ratio and the log-rank test results. The Imatinib mesylate arm had a hazard ratio of 0.378 and a P-value <0.0001 compared to IFN+Arc-C, indicating a significant difference in progression-free survival between the two treatments. Overall, the text describes the statistical results of a clinical trial evaluating the effectiveness of two different treatments for a medical condition.*

The text is presenting Figure 2 that illustrates the time to progression to AP or BC using the ITT principle. It shows the percentage of patients without progression and the number of patients with progression to AP or BC, censored at discontinuation and censored at last follow-up. The Hazard Ratio and Log-rank Test P-value are shown as well. The graph presents the two arms (Imatinib mesylate and IFN+Ara-C) and the months since randomization.*

Each tablet of the medicine contains 400mg of imatinib free base. The usual dosage can be found in the package insert. It must be stored at a temperature of 25°C (77°F) but excursions are permitted between 15-30°C (56-86°F) according to USP Controlled Room Temperature guidelines. It should be protected from moisture and dispensed in a tightly closed container, USP. This medicine is manufactured by Shilpa Medicare Limited in Jadcherla-509301, India and is distributed by Armas Pharmaceuticals, Inc. with the National Drug Code (NDC) 72485-203-30. No further information is available from the given text.*